NANO H5 & NANO H110 to provide result within 130 seconds
1st, June 2021: Trivitron Healthcare, a leading medical devices company has announced the launch of 2 new innovation driven products for HbA1c and Hb variant* detection. The new product includes NANO H5 & NANO H110 which are high performance liquid chromatography analyzers for HbA1c detection in less than 3 minutes.
These HPLC based HbA1c analyzers will be used for monitoring diabetes, thalassemia & hemoglobin variants.
NANO H5, is a compact, automated HPLC analyzer that uses ion exchange liquid chromatography for quantitative determination of the glycated haemoglobin (HbA1c) in human whole blood with processing time of 130 seconds that will expedite the laboratory TAT. The fully automated analyser which promises to process 5 samples at a time will take Trivitron Healthcare reach the pinnacle of precision within a designated time frame in the global diagnostic market.
NANO H110, is a compact, automated HPLC analyzer has a dual test mode for HbA1c test and Hb Variant* detection. It has some advance facilities such as Barcode scanner and cap piercing with a high sample loading capacity of 110 samples at a time which make it suitable for laboratories with medium to large workloads.
Rajesh Patel, Chief Executive Officer (IVD Business), Trivitron Healthcare on this occasion said that, “keeping in mind the increasing concern for management of diabetes and the growing demand for accurate measurement of HbA1c level, today we are delighted to announce the launch of HPLC based HbA1c analyzers - NANO H5 & NANO H110, that are compact and designed for precision.”
Trivitron Healthcare is committed to many such technological advancements in the global diagnostic field.
Since 1997, the journey of Trivitron Healthcare as a medical technology company providing affordable healthcare solutions weaves a fascinating thread of inspiration to many healthcare providers. Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 180 countries. With 13 certified manufacturing facilities in India, Finland, Turkey; Trivitron spearheads innovation in the fields of COVID-19 Products, In-Vitro Diagnostics, Imaging & Radiology, Radiation Protection, Newborn Screening, Critical Care and Operating Room Solutions, thus, engraving its name as a holistic healthcare provider.
Website: www.trivitron.com
*This story is published by VOH team*
Affordable Diagnostics player Aarthi Scans finds new investor in Tata Capital Gr
Mayo Clinic invests in Ratan Tata-backed cancer care platform Karkinos Healthcar
HempStreet announces partnership with MGC Pharma to revolutionise Global Phytome
GenWorks Health raises Rs 135 Cr from Somerset Indus Capital Partners, Morgan St
Leaders Discuss Urgent Priorities in Vaccination Against Food & Water Borne Infe
National Forum on World Liver Day: Striving for Healthy Liver for a Healthy Futu
National Digital Forum underlines urgent priorities on World Haemophilia Day
NEXT DIRECTIONS IN CONNECTED HEALTH
QURE.ai RAISES $40 MILLION IN FUNDING
EKINCARE RAISES $15Mn IN SERIES B FUNDING
A finger on the pulse – a research by Edelweiss General Insurance on the Mille
India's First Home Collection Phlebotomist Services For Women by Women: Credent
GLOBAL CONCLAVE PROMISES CLOSER COLLABORATION IN HEALTHCARE
Breast Cancer Panel Triggers Important Conversations
Trivitron Healthcare is recognized as Great Place to Work - Certified!
View All